Latest Health & Nutrition News and Videos
Neurotech seeks to accelerate commercialization
First subjects dosed in first-in-human Phase 1 c
Vandria announced it has closed a second Series A financing round, bringing total funding to $30.7 million (CHF 28.3 million). According to the company, new investors Hevolution Foundation and Dolby Family Ventures joined the round, which aims to advance its lead candidate, VNA‑318, into clinical trials. The company said VNA‑318 is an oral mitophagy inducer targeting central nervous system (CNS) diseases linked to mitochondrial dysfunction. Vandria claims preclinical data support its potential to clear damaged mitochondria and restore cellular energy balance, offering a new therapeutic approach for age-related neurodegenerative disorders. According to Vandria, proceeds from the financing will fund a first-in-human clinical study and expand research on additional pipeline candidates. The company said its broader strategy focuses on modulating mitochondrial quality control processes, including mitophagy, to treat diseases driven by cellular energy deficits. Vandria claims the successful fundraising reflects growing recognition of mitophagy as a therapeutic target and investor confidence in its scientific platform. The company said it has assembled a leadership team with expertise in mitochondrial biology and CNS drug development to guide VNA‑318 through clinical translation. Vandria also noted it plans to explore further applications of mitophagy modulation beyond CNS disorders, aiming to address a range of chronic diseases linked…
DeepLife secures $10m to advance AI platform des
Vancouver-based health technology company Prenuvo
Research links hidden visceral fat to abnormal p
Company targets metabolic, immunological and neu
Spain-based fund targets challenges posed by agi
How professional care can integrate personalized
Crypto investor-backed LongGame aims to fund tec
Clinical trial of company’s osteoporosis drug
Hooke London has partnered with Citius Retreats t
Dr Eric Verdin of The Buck Institute for Researc
Protect Animal Health and Rejuvenate Bio have ann
Promising data from Phase 2 study in myelodyspla
Company continues to advance NLRP3 neuroinflamma
Antag lands €80m to advance GIPR antagonist ap
World’s largest longevity event combines longe
Funding call for innovative scientific proposals